{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:47:14Z","timestamp":1767422834804},"reference-count":32,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,7]]},"abstract":"<jats:p>Disseminated strongyloidiasis is often fatal, despite treatment with oral albendazole and parenteral ivermectin (IVM). Here, we report elevated plasma IVM and albendazole sulfoxide concentrations in the context of extracorporeal membrane oxygenation and continuous renal replacement therapy in a patient with disseminated strongyloidiasis treated with subcutaneous IVM and nasogastric albenzadole. Despite elevated drug plasma concentrations, live filariform larvae were detected in endotracheal aspirates after 2 weeks of treatment.<\/jats:p>","DOI":"10.4269\/ajtmh.18-0487","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T07:01:05Z","timestamp":1537254065000},"page":"1194-1197","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Ivermectin and Albendazole Plasma Concentrations in a Patient with Disseminated Strongyloidiasis on Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy"],"prefix":"10.4269","volume":"99","author":[{"given":"Carl","family":"Boodman","sequence":"first","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yashpal S.","family":"Chhonker","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Centre, Omaha, Nebraska;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl J.","family":"Murry","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Centre, Omaha, Nebraska;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Mah","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Grant","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada;"},{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Libman","sequence":"additional","affiliation":[{"name":"J. D. MacLean Centre for Tropical Diseases, McGill University, Montreal, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesilia","family":"Nishi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marthe","family":"Charles","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"b1","series-title":"J Pharm Biomed Anal","first-page":"1013","article-title":"Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies","volume":"40","author":"Kitzman","year":"2006"},{"key":"b2","series-title":"J Pharm Biomed Anal","first-page":"84","article-title":"LC-MS\/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: application to a clinical pharmacokinetic study","volume":"151","author":"Chhonker","year":"2017"},{"key":"b3","series-title":"PLoS Negl Trop Dis","first-page":"e0005945","article-title":"Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers","volume":"12","author":"Ceballos","year":"2018"},{"key":"b4","series-title":"Eur J Clin Pharmacol","first-page":"705","article-title":"Pharmacokinetics of albendazole in man","volume":"30","author":"Marriner","year":"1986"},{"key":"b5","series-title":"J Parasitol Res","first-page":"818296","article-title":"Fatal outcome of disseminated strongyloidiasis despite detectable plasma and cerebrospinal levels of orally administered ivermectin","volume":"2009","author":"Rose","year":"2009"},{"key":"b6","series-title":"J Antimicrob Chemother","first-page":"220","article-title":"Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature","volume":"71","author":"Barrett","year":"2016"},{"key":"b7","series-title":"BMC Infect Dis","first-page":"78","article-title":"Severe strongyloidiasis: a systematic review of case reports","volume":"13","author":"Buonfrate","year":"2013"},{"key":"b8","series-title":"Can Commun Dis Rep","first-page":"12","article-title":"CATMAT statement on disseminated strongyloidiasis: prevention, assessment and management guidelines","volume":"42","author":"Boggild","year":"2016"},{"key":"b9","series-title":"Am J Trop Med Hyg","first-page":"94","article-title":"Failure of ivermectin per rectum to achieve clinically meaningful serum levels in two cases of Strongyloides hyperinfection","volume":"93","author":"Bogoch","year":"2015"},{"key":"b10","series-title":"Scand J Infect Dis","first-page":"234","article-title":"Serum ivermectin levels after enteral and subcutaneous administration for Strongyloides hyperinfection: a case report","volume":"42","author":"Grein","year":"2010"},{"key":"b11","series-title":"Braz J Infect Dis","first-page":"479","article-title":"Salvage treatment of disseminated strongyloidiasis in an immunocompromised patient: therapy success with subcutaneous ivermectin","volume":"16","author":"de Moura","year":"2012"},{"key":"b12","series-title":"Am J Trop Med Hyg","first-page":"911","article-title":"Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis","volume":"73","author":"Turner","year":"2005"},{"key":"b13","series-title":"Int J Antimicrob Agents","first-page":"580","article-title":"Strongyloides disseminated infection successfully treated with parenteral ivermectin: case report with drug concentration measurements and review of the literature","volume":"42","author":"Donadello","year":"2013"},{"key":"b14","series-title":"Am J Trop Med Hyg","first-page":"853","article-title":"Failure of subcutaneous ivermectin in treating Strongyloides hyperinfection","volume":"79","author":"Leung","year":"2008"},{"key":"b15","series-title":"Am J Trop Med Hyg","first-page":"879","article-title":"Non-oral treatment with ivermectin for disseminated strongyloidiasis","volume":"83","author":"Fusco","year":"2010"},{"key":"b16","series-title":"Clin Infect Dis","first-page":"e5","article-title":"Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin","volume":"41","author":"Marty","year":"2005"},{"key":"b17","series-title":"AAPS J","first-page":"42","article-title":"The pharmacokinetics and interactions of ivermectin in humans\u2014a mini-review","volume":"10","author":"Gonz\u00e1lez Canga","year":"2008"},{"key":"b18","series-title":"Antimicrob Agents Chemother","first-page":"211","article-title":"Sensitive in vitro system to assess morphological and biochemical effects of praziquantel and albendazole on Taenia solium cysts","volume":"55","author":"Mahanty","year":"2011"},{"key":"b19","series-title":"Clin Infect Dis","first-page":"334","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016"},{"key":"b20","series-title":"Croat Med J","first-page":"146","article-title":"Albendazolesulphoxide concentrations in plasma and hydatid cyst and prediction of parasitological and clinical outcomes in patients with liver hydatidosis caused by Echinococcus granulosus","volume":"55","author":"Skuhala","year":"2014"},{"key":"b21","series-title":"Antimicrob Agents Chemother","first-page":"944","article-title":"In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium","volume":"57","author":"Paredes","year":"2013"},{"key":"b22","series-title":"J Chromatogr B Analyt Technol Biomed Life Sci","first-page":"233","article-title":"Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography","volume":"799","author":"Sarin","year":"2004"},{"key":"b23","series-title":"J Pharm Biomed Anal","first-page":"84","article-title":"LC\u2013MS\/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: application to a clinical pharmacokinetic study","volume":"151","author":"Chhonker","year":"2018"},{"key":"b24","series-title":"J Clin Pharmacol","first-page":"28","article-title":"Clinical pharmacokinetics of albendazole in patients with brain cysticercosis","volume":"32","author":"Jung","year":"1992"},{"key":"b25","series-title":"Crit Care Med","first-page":"A286","article-title":"1132: use of single pass lipid dialysis for the treatment of avermectin toxicity","volume":"41","author":"Bolfer","year":"2013"},{"year":"2000","author":"Johnson","key":"b26"},{"key":"b27","series-title":"Crit Care","first-page":"66","article-title":"Medicating patients during extracorporeal membrane oxygenation: the evidence is building","volume":"21","author":"Dzierba","year":"2017"},{"key":"b28","series-title":"Crit Care","first-page":"R194","article-title":"Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation","volume":"16","author":"Shekar","year":"2012"},{"key":"b29","series-title":"J Antimicrob Chemother","first-page":"145","article-title":"Albendazole","volume":"41","author":"Venkatesan P","year":"1998"},{"key":"b30","series-title":"Travel Med Infect Dis","first-page":"625","article-title":"Strongyloidiasis in Ontario: performance of diagnostic tests over a 14-month period","volume":"14","author":"Dong","year":"2016"},{"key":"b31","series-title":"Crit Care","first-page":"243","article-title":"Clinical review: extracorporeal membrane oxygenation","volume":"15","author":"Gattinoni","year":"2011"},{"key":"b32","series-title":"J Infect","first-page":"18","article-title":"Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review","volume":"54","author":"Fardet","year":"2007"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/99\/5\/article-p1194.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/99\/5\/article-p1194.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/99\/5\/article-p1194.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T20:24:11Z","timestamp":1722457451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/99\/5\/article-p1194.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,7]]},"references-count":32,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.18-0487","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"type":"print","value":"0002-9637"},{"type":"electronic","value":"1476-1645"}],"subject":[],"published":{"date-parts":[[2018,11,7]]}}}